Winneup Injection

Adult administration

The dosage and infusion rate should be determined based on the patient's ability to eliminate fat, metabolic capabilities for nitrogen and glucose, and nutritional requirements. The dosage and bag size should be determined according to the patient's condition and weight. Patients with normal nutritional status or mild metabolic stress should receive nitrogen at a rate of 0.10-0.15 g/kg per day (0.6-0.9 g/kg as amino acids). Patients under moderate to severe metabolic stress should receive

This medicine should only be used according to a doctor's instructions, and if sudden allergic reactions such as fever, chills, rash, or breathing difficulties occur during use, administration must be stopped immediately. It should not be co-administered with other medications containing calcium via the vein, and the infusion line must be thoroughly cleaned. Particular caution is advised when using this medication in premature infants or low-birth-weight infants as it may pose risks. Patients allergic to fish, eggs, soybeans, peanuts, or those with severe liver, kidney, or blood disorders should not use this medication. Additionally, patients in acute shock or those with uncontrolled hyperglycemia should avoid administration. When administering this medication, the patient's condition must be carefully monitored, and blood electrolyte and fluid status should be checked regularly. Care must be taken in patients with lipid metabolism disorders, hyperlipidemia, or diabetes. In instances of overdose, symptoms such as fatty liver syndrome, amino acid excess, and hyperglycemia may occur, so the rate and dosage must be strictly controlled. This medication contains soybean oil, fish oil, and egg yolk lecithin, which can rarely cause allergic reactions, thus patients with a history of allergies should exercise caution. To prevent infection during administration, aseptic conditions should be maintained, the infusion site should be checked frequently, and regular blood tests and liver function tests should be conducted during long-term administration. Women who are pregnant or breastfeeding must carefully consider the safety of this medication in consultation with their doctor if necessary. This medication should be stored in a sealed container to prevent air and moisture ingress, and it is recommended to keep it at room temperature between 1°C and 25°C. This helps to maintain the drug's effectiveness and prevent deterioration.

Serious side effects

• Fever, rash, breathing difficulties → anaphylactic reaction
• Chest discomfort → severe allergic reaction
• Pulmonary vascular fat accumulation → severe respiratory problems
• Symptoms of fatty liver syndrome (hyperlipidemia, fever, jaundice, anemia, thrombocytopenia, coagulation disorders, coma, etc.) → liver abnormalities and severe systemic symptoms
• Fever, disease worsening, central nervous system depression, delirium, pneumonia, pulmonary embolism → serious adverse events
• Increased CRP → systemic disease
• Hyperglycemia

Mild side effects

• Dizziness
• abdominal pain
• upper abdominal pain
• dry mouth
• indigestion
• black stool
• nausea
• vomiting
• increased serum creatine phosphokinase
• increased serum lactate dehydrogenase

This medication should be stored in a sealed container to prevent air or moisture ingress, preferably at room temperature between 1°C and 25°C. This helps to maintain the effectiveness of the drug and prevent deterioration.

Appearance

This medicine consists of three compartments divided by an internal white and external package, with oxygen-absorbing agent pouches in between. Each compartment contains a dextrose solution, an amino acid and electrolyte solution, and

Package unit

736mL (Solution A 222mL, Solution B 374mL, Solution C 140mL) / bag, 1085mL (Solution A 328mL, Solution B 551mL, Solution C 206mL) / bag, 1435mL (Solution A 433mL, Solution B 729mL, Solution C 273mL) / bag, 1820mL (Solution A 550mL, Solution B 924mL, Solution C 346mL) / bag